Overview

Antibiotic Prophylaxis With Routine Ureteral Stent Removal

Status:
Recruiting

Trial end date:
2025-01-01

Target enrollment:
0

Participant gender:
All

Summary

This study will be a single-institutional randomized, single-blinded prospectively controlled clinical trial of a single dose of Ciprofloxicin 500mg antibiotic tablet as prophylaxis at the time of office flexible cystoscopy with ureteral stent removal. The control group will be no prophylaxis oral antibiotics.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University of California, San Diego

Collaborator:

Genesis HealthCare

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular
Ciprofloxacin
Sulfamethoxazole
Trimethoprim

Criteria

Age: >=18 years of age

Gender: both men and women included. We anticipated enrolling a study population of
approximately 60% men and 40% women based on a higher incidence of kidney stones among men
in NHANES data.

Ethnic background: all ethnicities will be included in the study population and the
specific ethnic diversity present in the study population will reflect the geographic
distributions of the participating institutions.

Health Status: see below for specific inclusion/exclusion criteria.

Inclusion criteria:

- Patients with indwelling ureteral stents placed within the 2 weeks prior to the
procedure visit for removal

- Patients having underwent kidney stone treatment surgery (shockwave lithotripsy [SWL],
ureteroscopy [URS], retrograde intrarenal surgery [RIRS], percutaneous nephrolithotomy
[PNL]) Exclusion criteria

- Patients with indwelling urethral catheter

- Patients with indwelling suprapubic catheter

- Patients with indwelling nephrostomy tube

- Patients who perform clean intermittent catheterization

- Pregnancy